DOGE Made Drastic Cuts to a Global Vaccine Assistance Program. Now There’s a Deadly Measles Outbreak in Bangladesh

Why It Matters

The abrupt funding decline jeopardizes decades of immunisation gains in Bangladesh and signals a looming global health crisis as reduced aid fuels preventable disease outbreaks.

Key Takeaways

• US AID funding for Bangladesh fell from $371M to $24M (2026)
• Measles deaths exceed 100 children; 900 cases reported since March
• Vaccine stockpile shortage linked to DOGE-driven US AID cuts
• 85% of US AID distribution cut globally, risking hundreds of thousands deaths
• Immunisation gains in Bangladesh now jeopardized, children left vulnerable

Pulse Analysis

The Department of Government Efficiency, a Musk‑backed initiative, has become a flashpoint for debate over the role of private‑sector efficiency drives in public health financing. By redirecting and curtailing US Agency for International Development (USAID) allocations, the program reduced Bangladesh's health aid from $371 million in 2024 to a mere $24 million in 2026. While the intent was to trim taxpayer expenditures, the rapid withdrawal left a critical vacuum in vaccine procurement, a sector that previously relied on steady US support for routine immunisations against measles, polio, diphtheria and tetanus.

In Bangladesh, the impact is stark. With over 100 child fatalities and 900 confirmed measles cases since March, the outbreak highlights how fragile health infrastructure can crumble under funding shocks. The United Nations has mobilised emergency vaccination campaigns, yet the shortage of doses hampers rapid containment. Health officials warn that children older than nine months—who are now eligible for measles shots—remain unprotected, reversing years of progress in child health indicators. The episode illustrates a direct causal chain: aid cuts → depleted stockpiles → vaccination gaps → disease resurgence.

Globally, the cuts echo a broader trend: the Center for Strategic and International Studies reports an 85% reduction in USAID disbursements across low‑income nations. This contraction threatens to reverse gains in disease control, potentially leading to hundreds of thousands of avoidable deaths. Policymakers must weigh short‑term fiscal savings against long‑term public health costs, exploring alternative financing mechanisms and resilient supply chains to safeguard immunisation programs from future political or budgetary swings.